April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal injection of bevacizumab for diabetic macula edema: morphological and functional outcomes at 1 day after injection.
Author Affiliations & Notes
  • Rieko Higashida
    Ophthalmology, Teikyo University School of Medicine, Kawasaki, Kanagawa, Japan
  • Yutaka Imamura
    Ophthalmology, Teikyo University School of Medicine, Kawasaki, Kanagawa, Japan
  • Atsushi Ishikawa
    Ophthalmology, Teikyo University School of Medicine, Kawasaki, Kanagawa, Japan
  • Yorihisa Tsutsumi
    Ophthalmology, Teikyo University School of Medicine, Kawasaki, Kanagawa, Japan
  • Yoshikazu Ichikawa
    Ophthalmology, Teikyo University School of Medicine, Kawasaki, Kanagawa, Japan
  • Takeshi Wakakuri
    Ophthalmology, Teikyo University School of Medicine, Kawasaki, Kanagawa, Japan
  • Masahiro Ishida
    Ophthalmology, Teikyo University School of Medicine, Kawasaki, Kanagawa, Japan
  • Footnotes
    Commercial Relationships Rieko Higashida, None; Yutaka Imamura, None; Atsushi Ishikawa, None; Yorihisa Tsutsumi, None; Yoshikazu Ichikawa, None; Takeshi Wakakuri, None; Masahiro Ishida, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1764. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rieko Higashida, Yutaka Imamura, Atsushi Ishikawa, Yorihisa Tsutsumi, Yoshikazu Ichikawa, Takeshi Wakakuri, Masahiro Ishida; Intravitreal injection of bevacizumab for diabetic macula edema: morphological and functional outcomes at 1 day after injection.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1764. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate and compare the visual and anatomical outcomes in eyes with diabetic macular edema (DME) at 1 day and 1 week after injection of intravitreal bevacizumab.

Methods: A retrospective, consecutive case series identified 21 consecutive patients with DME undergoing intravitreal injection of bevacizumab. Optical coherence tomography images were taken at the day of injection and 1-day and 1 week after injection. Retinal thickness at fovea and visual acuity were monitored before and after injection.

Results: The mean age of patients was 65.1 years old (10 females). Retinal thickness at fovea was 490 ± 169 µm before injection, and was 442 ± 162 µm and 335 ± 148 µm at 1 day and 1 week after injection. (Student t test, P=0.001 and 0.004, respectively) Visual acuity (logMAR) was 0.616±0.344 before injection and 0.682±0.413 and 0.425±0.237 at 1 day and 1 week after injection. (P=0.567 and 0.063, respectively)

Conclusions: Resolution of intraretinal fluids was observed at 1 day postoperatively, however at least 1 week is needed so that large amounts of fluids are absorbed in DME. Significant improvement of vision was not observed at 1 day and 1 week after injection. Intraretinal fluids seem to disappear more slowly in DME than those in retinal vein occulusion after intravitreal injection of bevacizumab (Ishikawa A, 2013 ARVO abstract).

Keywords: 498 diabetes • 550 imaging/image analysis: clinical • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×